Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 5,125 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HIV - Human Immunodeficiency Virus Clear all
Completed Not applicable Interventional Accepts healthy volunteers

UCLA-Amity Parolee Health Promotion Study

NCT01844414
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV, Drug Addiction
Interventions
Parolee Comprehensive Care + Phone Coach, Parolee Brief HBV Program + Phone Coach, Usual Care Group
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 6, 2026, 1:15 PM EDT
Not listed Not applicable Interventional

A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis

NCT00002158
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Nitazoxanide
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
3 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2007 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

NCT00000878
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)

NCT00002014
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines

NCT01172535
View directory record Official record
Conditions
HIV
Interventions
Lopinavir/ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Weeks and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Not applicable Interventional Results available

Effects of Growth Hormone Releasing Hormone in HIV

NCT01263717
View directory record Official record
Conditions
HIV, HIV Lipodystrophy
Interventions
tesamorelin, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

NCT00054717
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
96
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 2 Interventional

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination

NCT00001132
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
29
States / cities
Los Angeles, California • Menlo Park, California • San Jose, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Oct 6, 2026, 1:15 PM EDT
Terminated Not applicable Interventional

Implementing Cabenuva in Arkansas HIV Programs

NCT05096949
View directory record Official record
Conditions
HIV-1-infection, Medication Adherence, Satisfaction, Patient
Interventions
Home visit delivery strategy
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 6, 2026, 1:15 PM EDT
Terminated Not applicable Interventional

Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients

NCT00655226
View directory record Official record
Conditions
Hepatitis C, Depressive Disorder, Major, Depressive Disorder, Depression, HIV Infections
Interventions
Hepatitis C educational support groups, Cognitive Behavioral Therapy skills based group sessions
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2011 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 1 Interventional

Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects

NCT00000740
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Sitamaquine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 1 Interventional

An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)

NCT00002255
View directory record Official record
Conditions
HIV Infections
Interventions
Filgrastim, Epoetin alfa, Zidovudine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

NCT00486408
View directory record Official record
Conditions
HIV Infections
Interventions
MRKAd5 HIV-1 gag/pol/nef
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
4
States / cities
Birmingham, Alabama • Rochester, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 6, 2026, 1:15 PM EDT
Completed No phase listed Observational

Body Image in Youth With HIV

NCT01673750
View directory record Official record
Conditions
Human Immunodeficiency Virus, HIV
Interventions
Questionnaire
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
16 Years to 23 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 6, 2026, 1:15 PM EDT
Completed No phase listed Observational Results available

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

NCT05794191
View directory record Official record
Conditions
HIV, Pneumonia, Infections, Pneumococcal
Interventions
Vaccine Administration
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350,399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 6, 2026, 1:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Recruiting African American Fathers/ Sons

NCT02811848
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
10 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention

NCT06059443
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Viral, Syphilis
Interventions
mLab App Plus
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients

NCT00002450
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 1:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cannabis, HIV and Mental Processing Systems

NCT05430490
View directory record Official record
Conditions
HIV Infections, Cannabis
Interventions
MRI, NeuroPsychological Testing, Blood Draw, Questionnaires, Lumbar Puncture
Procedure · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 6, 2026, 1:15 PM EDT
Withdrawn Phase 4 Interventional

A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C

NCT02206932
View directory record Official record
Conditions
Hepatitis C, Chronic, HIV CDC Category A1
Interventions
Sofosbuvir + Simeprevir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).

NCT00000393
View directory record Official record
Conditions
HIV Infections, Cognition Disorders
Interventions
Peptide T
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1988
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 1 Interventional

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

NCT00503347
View directory record Official record
Conditions
Hepatitis C Virus, Hiv Infections
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Oct 6, 2026, 1:15 PM EDT
Completed No phase listed Observational

A Study of Health-Related Quality of Life in HIV-Infected Patients Undergoing Structured Treatment Interruptions of Highly Active Antiretroviral Therapy

NCT00001948
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 6, 2026, 1:15 PM EDT
Completed Phase 2 Interventional

Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

NCT00000626
View directory record Official record
Conditions
HIV Infections, Hodgkin's Disease
Interventions
Vinblastine sulfate, Dacarbazine, Filgrastim, Bleomycin sulfate, Doxorubicin hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 6, 2026, 1:15 PM EDT